Skip to main content
Evidence Snapshot

Toll-like receptor 9

CHEMBL5804 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5804
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Toll-like receptor 9 as ChEMBL target CHEMBL5804, mapped to UniProt Q9NR96. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Toll-like receptor 9
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5804
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NR96
Toll-like receptor 9
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Toll-like receptor 9 matters

As of 2026-09-14

Toll-like receptor 9 is reviewed as Toll-like receptor 9 (UniProt Q9NR96); Toll-like receptor 9 shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 4132 compounds, and 109 assays, with lead potency reaching pChEMBL 8.5.

Disease context
malaria

Toll-like receptor 9 shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AGATOLIMOD SODIUM, HYDROXYCHLOROQUINE SULFATE.

Start review with malaria because it currently carries approved-linked support. Linked drugs include AGATOLIMOD SODIUM, HYDROXYCHLOROQUINE SULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 4132 compounds, and 109 assays for this target. The dominant activity type is IC50. CHEMBL3356618 is the current potency anchor at pChEMBL 8.5.

Use CHEMBL3356618 as the tractability anchor when discussing potency (pChEMBL 8.5).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 8.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Toll-like receptor 9 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9NR96, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why malaria is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4132
Total Compounds
109
Total Assays
1
Approved Drugs
IC50: 7251.0, EC50: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3356618
 8.5 IC50 —
No preferred name
CHEMBL3357062
 8.4 IC50 —
No preferred name
CHEMBL2144205
 8.3 IC50 —
No preferred name
CHEMBL5169681
 8.3 IC50 —
No preferred name
CHEMBL5094930
 8.2 IC50 —

Approved Drugs

Structure Compound First Approval
HYDROXYCHLOROQUINE
CHEMBL1535
 1955
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5804